Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;78(3):882-885.
doi: 10.1111/all.15627. Epub 2023 Jan 4.

IL-5 receptor expression in lung fibroblasts: Potential role in airway remodeling in asthma

Khuloud Bajbouj  1   2 , Rola AbuJabal  1   2 , Lina Sahnoon  2 , Ronald Olivenstein  3 , Bassam Mahboub  4 , Qutayba Hamid  1   2   3
Affiliations

IL-5 receptor expression in lung fibroblasts: Potential role in airway remodeling in asthma

Khuloud Bajbouj et al. Allergy. 2023 Mar.
No abstract available

Keywords: IL-5 receptor; airway fibroblasts; asthma; fibrosis.

PubMed Disclaimer

References

REFERENCES

    1. Murray CS. Can inhaled corticosteroids influence the natural history of asthma? Curr Opin Allergy Clin Immunol. 2008;8(1):77-81.
    1. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for IL-5 in mucosal bronchial biopsies from asthma. Clin Invest. 1991;87(5):1541-1546.
    1. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4 + T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in atopic asthmatics. Allergy Clin Immunol. 1993;92(2):313-324.
    1. Lamkhioued B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. Immunology. 1997;9(159):4593-4601.
    1. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141.

Publication types